Carbon Nanoparticle Composition for Ocular Angiogenesis Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for ocular angiogenesis, such as anti-angiogenesis therapy using anti-vascular endothelial growth factor (VEGF), require frequent injections and can cause severe side effects like endophthalmitis and retinal detachment.
Innovation Solution
Production of carbon nanoparticles through pyrolysis of sodium alginate and a C4-C10 linear aliphatic diamine at 160° C. to 200° C., which are administered to inhibit VEGF-induced cell migration and choroidal neovascularization without severe side effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If anti-angiogenesis therapy using anti-VEGF is administered, then ocular angiogenesis is inhibited, but frequent injections are required and severe side effects occur
Solution Approach 1:
The patent changes the chemical structure parameters by introducing a cyclic structure with specific functional groups (carboxylic acid, hydroxyl, amine) at controlled positions on the carbon nanoparticle surface. This structural parameter modification enables the particle to interact with VEGF in a novel manner, achieving anti-angiogenesis effects through a different mechanism than conventional anti-VEGF antibodies, thereby reducing side effects while maintaining therapeutic efficacy
Solution Approach 2:
The patent creates a composite material system consisting of carbon core nanoparticles functionalized with specific organic groups (carboxylic acid, hydroxyl, amine). This composite structure combines the stability and penetration capability of carbon nanoparticles with the biological activity of functional groups, producing a therapeutic agent that achieves reliable anti-angiogenesis effects with reduced toxicity compared to conventional treatments
2Reliability
If anti-angiogenesis therapy using anti-VEGF is administered, then ocular angiogenesis is inhibited, but administration frequency must be high
Solution Approach 1:
The patent modifies the physical-chemical parameters of the therapeutic agent by creating nanoparticles with specific size ranges (5-50 nm diameter) and controlled surface functional group densities. These parameter changes enhance the pharmacokinetic properties, including extended circulation time and prolonged retention in the ocular tissue, thereby maintaining reliable anti-angiogenesis effects over extended periods and reducing administration frequency
Solution Approach 2:
The patent employs carbon nanoparticles with multiple functional groups (carboxylic acid, hydroxyl, amine) that can simultaneously engage in multiple interactions with VEGF and surrounding tissue. This multi-point binding approach creates a stronger and more sustained therapeutic effect per administration, extending the duration of action and reducing the need for frequent injections
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The carbon nanoparticles effectively inhibit ocular angiogenesis by reducing cell migration and tube formation, alleviating tissue damage in the eye without causing significant adverse effects.
Implementation Method 1
subjecting sodium alginate and a diamine to a pyrolysis treatment at a temperature ranging from 160° C. to 200° C.
Data Source
AI summary
A carbon nanoparticle, which is produced by the step of subjecting sodium alginate and a diamine to a pyrolysis treatment at a temperature ranging from 160° C. to 200° C. The diamine is a C4-C10 linear aliphatic diamine. A method for alleviating ocular angiogenesis using the carbon nanoparticle and a method for producing the carbon nanoparticle are also provided.